Navigation Links
National Institutes of Health Bestows Grant to NeuroEM Therapeutics and Arizona State University for Collaborative Research in Alzheimer's Disease
Date:12/8/2016

PHOENIX, Dec. 8, 2016 /PRNewswire/ -- A Small Business Innovative Research (SBIR) grant has been awarded by the National Institutes of Health (NIH) to Phoenix-based NeuroEM Therapeutics, Inc. and Arizona State University. 

The grant will seek to determine an optimal set of treatment parameters for NeuroEM's head device, which utilizes electromagnetic waves to treat Alzheimer's Disease. The grant will also investigate the potential of this novel technology to possibly treat other neurologic disorders such as Parkinson's Disease and PTSD.

NeuroEM's transcranial electromagnetic treatment (TEMT) head device is currently in clinical trials in Alzheimer's patients. The trial involves TEMT device settings that proved effective in protecting against and reversing memory impairment in Alzheimer's mice. 

This newly-awarded Phase I SBIR grant, administered by the National Institute for Neurologic Disease and Stroke (NINDS), will investigate if changes in various TEMT parameters result in even more benefit. Treatment benefits will be determined by the ability of TEMT to break-up small abnormal proteins (amyloid and tau oligomers) that are thought to initiate and propagate the Alzheimer's Disease process.

At ASU, the collaborative research involves Dr. Michael Sierks of ASU's Dept. of Chemical Engineering, Dr. Jeffrey Yager of ASU's Magnetic Resonance Research Center, and Dr. James Aberle of ASU's Department of Electrical Engineering.

"As a clinical-stage medical device company, NeuroEM is delighted to collaborate with ASU researchers in this important multi-disciplinary effort," said Dr. Gary Arendash, President and CEO of NeuroEM Therapeutics. "ASU offers a rich diversity of technologies and expertise in biomedical research that make it an ideal partner to collaborate with." 

Only a small portion of grants submitted to the SBIR program at NIH are funded. For example, last year, only four SBIR Phase I grants for medical research were awarded within the state of Arizona. 

In awarding the present grant, NIH and NINDS are acknowledging that there is real merit to the new TEMT technology developed by NeuroEM against Alzheimer's and that the collaboration with ASU could result in substantial advancement of that novel technology.

NeuroEM's Phase I clinical trial involving treatment of Alzheimer's patients with their TEMT head device, is being performed at Banner Sun Health Research Institute and Banner Alzheimer's Institute, both in Phoenix. "Especially given the partnership between ASU and Phoenix-based Banner Health, the collaboration that NeuroEM Therapeutics has with both of these distinguished institutions could result in real therapeutic progress against the devastating memory impairment of Alzheimer's Disease," said Dr. Arendash. 

Although many drugs have been clinical tested in Alzheimer's patients over the past 15 years, none of them have thus far been shown to be effective in slowing down or reversing the memory impairment of Alzheimer's Disease. NeuroEM and collaborating ASU researchers believe, however, that the new technology of TEMT has real potential against Alzheimer's. This is in part because TEMT therapy can effect/treat all areas of the brain and in part because TEMT has several mechanisms of action that appear to be disease-modifying.

Arizona is a major hub of both basic and clinical research into Alzheimer's Disease. It would be a real accomplishment within the state of Arizona if the basic science and clinical collaborations between NeuroEM Therapeutics, ASU, and Banner Health could demonstrate TEMT as the first truly effective therapeutic against this dreaded disease.

About NeuroEM Therapeutics, Inc.
NeuroEM Therapeutics is a clinical–stage medical device company focused on development of Transcranial Electromagnetic Treatment (TEMT) to treat neurodegenerative disorders such as Alzheimer's Disease, Traumatic Brain Injury, and Down's Syndrome. The company is headquartered in Phoenix, AZ. For more information about NeuroEM Therapeutics, go to www.neuroem.com.

Contact:
Dr. Gary W. Arendash
NeuroEM Therapeutics Inc.
137122@email4pr.com 
(480) 395-1481

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/national-institutes-of-health-bestows-grant-to-neuroem-therapeutics-and-arizona-state-university-for-collaborative-research-in-alzheimers-disease-300375215.html


'/>"/>
SOURCE NeuroEM Therapeutics, Inc.
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. AlloSource Business Process Manager Designated Malcolm Baldrige National Quality Award Examiner, Deepening Companys Commitment To Performance Excellence
2. International Isotopes Inc. Submits Abbreviated New Drug Application For Sodium Iodide I-131
3. SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of PAREXEL International Corporation (PRXL)
4. International Cannabis Industry Association (ICIA) Raises Awareness for Floridians to Get Out and Vote "Yes" on Amendment #2
5. 28 States Fail to Protect Their Residents from the Opioid Crisis, says National Safety Council
6. National Pharmaceutical Council Welcomes Mallinckrodt as Its Newest Member
7. Aytu BioScience to Execute Reverse Stock Split in Anticipation of Uplisting its Common Stock to a National Exchange
8. Diamond Bur Market 2016-2021 International Outlook, Trends and Analysis
9. The Israeli Pharma Company Therapix, is Joined by Five Internationally Renowned Experts, From Israel and the World, in the Field of Psychiatry and Tourette
10. Debiopharm International SA Initiates Clinical Phase II Study Evaluating Debio 1143 in Ovarian Cancer
11. Sheryl Crow Named Hologics National Celebrity Spokesperson for New Breast Cancer Educational Campaign
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/13/2017)... has been named the official orthopedic and sports medicine ... 2018 College Football Playoff (CFP) National Championship to be played ... Atlanta, Georgia . OrthoAtlanta is proud to be ... many activities leading up to, and including the national championship ... OrthoAtlanta serves ...
(Date:9/9/2017)... NEW YORK , Sept. 8, 2017 ... largest independent supplier of medical equipment, supplies, drugs, ... that it has entered into an agreement to acquire ... surgical equipment based in Holtsville, New York ... which specializes in supplying new and emerging medical practices, ...
(Date:9/7/2017)... NuvoAir (formerly called Pond Healthcare Innovation), ... partnership with Novartis Pharma AG to distribute NuvoAir,s spirometry technology ... leading mobile spirometry platform and Novartis, commitment to address the ... ... ...
Breaking Medicine Technology:
(Date:9/22/2017)... ... 2017 , ... SABRE is pleased to announce the ... a graduate student from Sonora, California, who will begin her studies this fall ... in Miami, Florida, was selected from a pool of more than 50,000 applicants ...
(Date:9/22/2017)... ... September 22, 2017 , ... TopConsumerReviews.com recently awarded their ... that helps promote pancreatic health and regulate blood sugar levels . , ... can have negative side effects, and with the changes in today’s healthcare industry, ...
(Date:9/22/2017)... ... September 22, 2017 , ... “Fruit of the Spirit: “Love””: ... nature that God has created. “Fruit of the Spirit: “Love”” is the creation of ... devoted wife and mother of five. Halimah is an avid writer, her inspiration for ...
(Date:9/22/2017)... ... September 22, 2017 , ... Global Lyme Alliance (GLA), the ... and awareness, today announced the appointment of Timothy J. Sellati, Ph.D. as its ... more than 20 years of research experience with Lyme and other tick-borne diseases. ...
(Date:9/21/2017)... IL (PRWEB) , ... September 21, 2017 , ... SABRE ... to run from September 11 to the end of November. , The Chicago, Illinois, ... to their community and teach them about the ease of taking their personal safety ...
Breaking Medicine News(10 mins):